|
Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry incubated at the Technion-Israel Institute of Technology (Haifa, Israel) in 1994 and emerged as an independent company in 2001. The company's mission is to become a major player in managing high risk pregnancies by commercialising a novel technology platform of versatile cutting edge biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of novel diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies. DTL's lead product is placental protein-13 (PP13) - a sensitive and selective biomarker to screen for preeclampsia, intrauterine growth restriction and preterm delivery. There exists a critical mass of data in the scientific literature linking PP13 to proper placental implantation, anchoring and function (Placenta 2/2004, Eur. J. Biochem. 271, 67-71 (2004) – FEBS 2004). DTL is the first group to complete the development of product predicting preeclampsia in the first trimester.
|
